Objectives: to evaluate the effects of tofacitinib (TOFA) on cardiovascular risk factors (CVRF) in rheumatoid arthritis (RA) patients (pts). Methods: After 12-m follow-up the CVRF dynamic was assessed in 28 RA pts treated with TOFA (22 women, median age 54 [40; 62] years, disease duration 39. 5 [16.5; 60.0] m, moderate to high activity (DAS28 -5.1 [4.6; 6.0], 34]), positive for ACCP (75%)/RF (79%), who were non-responders to MTX at least 15 mg/week and/or other synthetic DMARDs and biologic DMARDs. TOFA therapy was started in all pts with dose 5 mg BID per os followed by the dose escalation to 10 mg BID in 8 (29%) pts. TOFA used in combination with MTX in 27 (96%) pts, leflunomide in 1 (4%). Low-dose oral corticosteroids (<10 mg/day prednisone or equivalent) were received by 9 (35%) pts. Remission or low disease activity was achieved in 55% pts (DAS28), 77% (SDAI). At baseline the most of pts had multiple CVRF and subclinical organ damage. Cardioprotective therapy received 16 (57%) pts (beta-blockers -7, angiotensin II receptor type 2/ACE inhibitors -11, statins -11, dihydropyridine calcium channel blockers -7). Results: The incidence rate of arterial hypertension (67% vs 70%), overweight (57% vs 72%), abdominal obesity (61% vs 68%), physical inactivity (64% vs 47%), smokers/ex-smokers (25%/21% vs 21%/25%), menopausal status (59% vs 59%), DM type 2 (7% vs 7%), mSCORE≥5% (21% vs 28%), subclinical carotid atherosclerosis (64% vs 64%), cardiac heart failure with preserved ejection fraction (7% vs 7%) did not change significantly. Blood pressure remained stable over time except 1 pt. An increase in body mass index (BMI) was observed from 26. 2 [22.9; 28.9] 91 [80; 103], p=0,001. The increase of BMI <5% was observed in 11 (39%) pts, 5% -10% -7 (25%), >10% -6 (21%). The normal BMI remained in 7 (25%) pts, overweight -9 (32%), obese class I -3 (11%), the rest of pts passed to a higher category of BMI (from normal BMI to overweight -4 (14%), from overweight to obese class I -1 (4%), from obese class I to obese class II -1 (4%)) and only 1 pt went from underweight to normal BMI (4%). The change in BMI correlated negatively with DAS 28, SDAI at baseline (r=-0.6, p<0.001).
FRI0231 THE FIRST REPORT OF SIGNIFICANT INCREASE OF BODY MASS INDEX IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH TOFACITINIB DURING 12-MONTH FOLLOW-UP
D. Novikova, I. Kirillova, E. Luchikhina, E. Markelova, H. Udachkina, N. Demidova, A. Misiyuk, T. Popkova, A. Volkov, L. Denisov, D. Karateev.
V.A.Nasonova Research Institute of Rheumatology, Moscow, Russian Federation
Objectives: to evaluate the effects of tofacitinib (TOFA) on cardiovascular risk factors (CVRF) in rheumatoid arthritis (RA) patients (pts). Methods: After 12-m follow-up the CVRF dynamic was assessed in 28 RA pts treated with TOFA (22 women, median age 54 [40; 62] years, disease duration 39.5 [16.5; 60.0] m, moderate to high activity (DAS28 -5.1 [4.6; 6.0], 34] ), positive for ACCP (75%)/RF (79%), who were non-responders to MTX at least 15 mg/week and/or other synthetic DMARDs and biologic DMARDs. TOFA therapy was started in all pts with dose 5 mg BID per os followed by the dose escalation to 10 mg BID in 8 (29%) pts. TOFA used in combination with MTX in 27 (96%) pts, leflunomide in 1 (4%). Low-dose oral corticosteroids (<10 mg/day prednisone or equivalent) were received by 9 (35%) pts. Remission or low disease activity was achieved in 55% pts (DAS28), 77% (SDAI). At baseline the most of pts had multiple CVRF and subclinical organ damage. Cardioprotective therapy received 16 (57%) pts (beta-blockers -7, angiotensin II receptor type 2/ACE inhibitors -11, statins -11, dihydropyridine calcium channel blockers -7). Results: The incidence rate of arterial hypertension (67% vs 70%), overweight (57% vs 72%), abdominal obesity (61% vs 68%), physical inactivity (64% vs 47%), smokers/ex-smokers (25%/21% vs 21%/25%), menopausal status (59% vs 59%), DM type 2 (7% vs 7%), mSCORE≥5% (21% vs 28%), subclinical carotid atherosclerosis (64% vs 64%), cardiac heart failure with preserved ejection fraction (7% vs 7%) did not change significantly. Blood pressure remained stable over time except 1 pt. An increase in body mass index (BMI) was observed from 26. 2 [22.9; 28.9] 91 [80; 103] , p=0,001. The increase of BMI <5% was observed in 11 (39%) pts, 5% -10% -7 (25%), >10% -6 (21%). The normal BMI remained in 7 (25%) pts, overweight -9 (32%), obese class I -3 (11%), the rest of pts passed to a higher category of BMI (from normal BMI to overweight -4 (14%), from overweight to obese class I -1 (4%), from obese class I to obese class II -1 (4%)) and only 1 pt went from underweight to normal BMI (4%). The change in BMI correlated negatively with DAS 28, SDAI at baseline (r=-0.6, p<0.001).
BMI dynamic was independent of TOFA dose, achieving RA activity Background: Poor prognostic factors (PPFs; e.g. elevated anti-citrullinated protein antibody/RF levels and erosions) are associated with higher disability and mortality in RA.
1-2 In addition, high seropositivity or CRP/ESR levels are correlated with erosive disease. Objectives: To evaluate if the presence of specific PPFs of seropositivity with erosions (PPF+) in patients (pts) with RA have an effect on treatment with abatacept (ABA) and anti-TNFs. Methods: This retrospective study was based on electronic medical record data. This database includes >6500 pts with RA from 50+ rheumatologists. At each visit, data on diagnosis, medications and test results were collected. A homunculus was used to record joint tenderness, swelling, deformity or decreased range of motion. Disease activity was measured by DAS28 (ESR/CRP), SDAI, CDAI, RAPID3 and Vectra DA blood tests. For this analysis, pts aged ≥18 yrs with an RA diagnosis from 1 Jan 2009 to 3 Mar 2016 were followed until lost to follow-up, death or end of study period. Date of first ABA/anti-TNF prescription was designated as index date, preceded by the baseline (BL) period. The ABA cohort comprised pts with a record of ABA in the study period, while the anti-TNF cohort comprised pts with a record of anti-TNF and no record of ABA in the study period. Primary outcome was change ( ) in CDAI at 6 months (M); other outcomes were SDAI, DAS28 (CRP), pain, RAPID3 and Patient Global Assessment. Descriptive statistics were used for BL characteristics. Univariate and multivariate regression analyses were
